Newron Pharmaceuticals S.p.A. (FRA:NP5)

Market Cap	335.82M +102.8%
Revenue (ttm)	19.13M -62.8%
Net Income	-13.24M
EPS	-0.66
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,750
Average Volume	298
Open	16.30
Previous Close	16.28
Day's Range	15.62 - 16.30
52-Week Range	5.91 - 33.55
Beta	n/a
RSI	38.95
Earnings Date	Mar 24, 2026

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NP5